Keyphrases
Hemophilia
97%
Pediatric
92%
Thrombin Generation
75%
Pediatric Patients
52%
Emicizumab
51%
B Cells
33%
Venous Thromboembolism
32%
Activated Protein C
29%
Bleeding
26%
Rare Bleeding Disorders
26%
Thrombosis
25%
Anticoagulant Treatment
25%
T Cells
24%
Factor VIII (FVIII)
23%
FVIII Inhibitors
21%
Severe Haemophilia A
21%
Recombinant Activated Factor VII (rFVIIa)
21%
Bleeding Episodes
20%
Hemostasis
19%
Thrombophilia
19%
Splanchnic Vein Thrombosis
19%
Glanzmann Thrombasthenia
19%
Literature Trends
19%
Text Mining
19%
Rivaroxaban
19%
High-level Analysis
19%
NLRP3 Inflammasome
19%
Myopic Choroidal Neovascularization (mCNV)
19%
Inherited Thrombophilia
19%
Hemophilia A Carrier
19%
Thrombocytopenia
19%
Hemophilia B
17%
FEIBA
17%
Immune Thrombocytopenia
16%
Pediatric Population
15%
Haemophilia with Inhibitors
15%
Bleeding Complications
15%
Etiology
14%
Risk Factors
14%
Clinical Characteristics
13%
Factor VIII Inhibitor
13%
Pediatric Research
13%
Gene Therapy
12%
Clinical Trials
12%
Estimated Incidence
12%
Bleeding Phenotype
12%
Direct Oral Anticoagulants
11%
Retina
11%
Treatment Options
11%
Immune Tolerance Induction
11%
Medicine and Dentistry
Pediatrics
100%
Haemophilia A
76%
Thrombin
64%
Emicizumab
52%
Bleeding
46%
Hemostat
42%
Patient with Hemophilia
39%
Pediatrics Patient
38%
Haemophilia
32%
Blood Stasis
30%
Phlebothrombosis
29%
Bleeding Disorder
28%
Activated Protein C
28%
Thrombophilia
26%
Thrombosis
25%
Anticoagulant Therapy
24%
Venous Thromboembolism
22%
Activated Prothrombin Complex
21%
Disease
20%
Ex Vivo
20%
Glanzmann's Thrombasthenia
19%
Choroidal Neovascularization
19%
NLRP3 Inflammasome
19%
Systematic Review
19%
Haemophilia B
18%
Recurrent Disease
18%
Immunological Tolerance
16%
Cancer
16%
Substitution Therapy
16%
Prospective Study
16%
Thrombocytopenia
14%
Malignant Neoplasm
14%
Blood Clotting Factor 8 Inhibitor
13%
Gene Therapy
12%
Clinical Trial
12%
Direct Oral Anticoagulant
11%
Ciclonicate
11%
Neonate
11%
Thromboelastography
11%
Interleukin-1
11%
Microglia
11%
Meta-Analysis
11%
Blood Clotting Factor
11%
Vasculotropin
10%
Inflammatory Cell
10%
Bleeding Diathesis
10%
T Cell
9%
Factor V
9%
Invasive Procedure
9%
Splenic Infarction
9%